REFERENCES
1 . Wolchok JD , Kluger H , Callahan MK , et al . Nivolumab plus ipilimumab in advanced melanoma . N Engl J Med . 2013 ; 369:122 – 133 2 . FDA Label for Proleukin ®. Available at http :// www . accessdata . fda . gov / drugsatfda _ docs / label / 2012 / 103293s5130lbl . pdf .
3 . McGinley L . Bloomberg , others give Hopkins $ 125 million for cancer research that helped Jimmy Carter . The Washington Post . March 29 , 2016 . Available at https :// www . washingtonpost . com / news / to-your-health / wp / 2016 / 03 / 29 / bloomberg-others-give-hopkins- 125-million-for-cancer-research-that-helped-jimmy-carter /
4 . Masters GA , Krilov L , Bailey HH , Brose MS , Burstein H , Diller LR , Dizon DS , Fine HA , Kalemkerian GP , Moasser M , Neuss MN , O ’ Day SJ , Odenike O , Ryan CJ , Schilsky RL , Schwartz GK , Venook AP , Wong SL , Patel JD . Clinical cancer advances 2015 : annual report on progress against cancer from the American Society of Clinical Oncology . J Clin Oncol 2015 . epub ahead of print
5 . Nguyen T , Urban J , Kalinski P . Therapeutic cancer vaccines and combination immunotherapies involving vaccination . ImmunoTargets Ther 2014 ; 3:135 – 50 .
6 . FDA . Nivolumab . Available at http :// www . fda . gov / Drugs / InformationOnDrugs / ApprovedDrugs / ucm427807 . htm . Accessed on February 21 , 2015 .
7 . Robert C , Long GV , Brady B , Dutriaux C , Maio M , Mortier L , Hassel JC , Rutkowski P , McNeil C , Kalinka-Warzocha E , Savage KJ , Hernberg MM , Lebbe C , Charles J , Mihalcioiu C , Chiarion-Sileni V , Mauch C , Cognetti F , Arance A , Schmidt H , Schadendorf D , Gogas H , Lundgren-Eriksson L , Horak C , Sharkey B , Waxman IM , Atkinson V , Ascierto PA . Nivolumab in previously untreated melanoma without BRAF mutation . N Engl J Med 2015 ; 372:320-330 .
8 . Topalian SL , Hodi FS , Brahmer JR , Gettinger SN , Smith DC , McDermott DF , Powderly JD , Carvajal RD , Sosman JA , Atkins MB , Leming PD , Spigel DF , Antonia SJ , Horn L , Drake CG , Pardoll DM , Chen L , Sharfman WH , Anders RA , Taube JM , McMiller TL , Xu H , Korman AJ , Jure-Kunkel M , Agarwal S , McDonald D , Kollia GD , Gupta A , Wigginton JM , Sznol M . Safety , activity , and immune correlates of anti-PD-1 antibody in cancer . N Engl J Med 2012 ; 366:2443-2454 .
9 . Shtivelman E . Immune system-boosting drugs , new and old , are explored in combination treatments for lung cancer . Cancer Commons . October 6 , 2014 .
10 . Mahoney KM , Rennert PD , Freeman GJ . Combination cancer immunotherapy and new immunomodulatory targets . Nature Reviews 2015 ; 14:561-584 .
11 . Drake CG . Combination immunotherapy approaches . Annals of Oncology 2012 ; 23 : vii41-vii46 . 12 . Bartkowiak T , Curran MA . 4-1BB agonists : multi-potent potentiators of tumor immunity . Front Oncol 2015 ; 5:117 .
13 . European Medicines Agency . Guideline on evaluation of anticancer medicinal products in man . February 25 , 2016 . Available at http :// www . ema . europa . eu / docs / en _ GB / document _ library / Scientific _ guideline / 2016 / 03 / WC500203320 . pdf
14 . Houot R , Goldstein MJ , Kohrt HE , Myklebust JH , Alizadeh AA , Lin JT , Irish JM , Torchia JA , Kolstad A , Chen L , Levy R . Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion . Blood 2009 ; 114:3431-3438 .
18
15 . Postow MA , Callahan MK , Barker CA , Yamada Y , Yuan J , Kitano S , et al . Immunologic correlates of the abscopal effect in a patient with melanoma . N Engl J Med 2012 ; 366:925-931 .